Unveiling 7 Analyst Insights On GoodRx Holdings

GoodRx Holdings GDRX has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.5, a high estimate of $6.00, and a low estimate of $4.50. Experiencing a 27.34% decline, the current average is now lower than the previous average price target of $7.57.

Interpreting Analyst Ratings: A Closer Look

The standing of GoodRx Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GoodRx Holdings. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of GoodRx Holdings compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of GoodRx Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on GoodRx Holdings analyst ratings.

Get to Know GoodRx Holdings Better

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers other healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Unraveling the Financial Story of GoodRx Holdings

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Negative Revenue Trend: Examining GoodRx Holdings's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -3.93% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: GoodRx Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -21.39% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): GoodRx Holdings's ROE excels beyond industry benchmarks, reaching -4.33%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): GoodRx Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.26% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.81.

The Core of Analyst Ratings: What Every Investor Should Know

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.